Furthermore, EGCG treatment inhibited oxidative stress, as evaluated by SOD, GPx, and MDA levels, and inflammation-related factors, including IL-1β, IL-6, TNF-α, and vascular endothelial growth factor (VEGF), in HDF-BPH rats. Here, IL6 is linked to benign prostatic hyperplasia.